We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Simple Blood Tests for Signaling Proteins Could Predict Cancer or Inflammation

By LabMedica International staff writers
Posted on 24 Feb 2023

Telomeres, sections of DNA found at the ends of our chromosomes, were first identified by scientists around 80 years ago. More...

Telomeres contain a unique DNA sequence consisting of endless repeats of TTAGGG bases that prevent chromosomes from sticking to each other. Telomeres were once believed to be incapable of encoding proteins due to their simple monotonous repetitions of DNA. Two decades ago, researchers demonstrated that the end of a telomere’s DNA loops back on itself to form a tiny circle, thereby hiding the end and blocking chromosome-to-chromosome fusions. When cells divide, telomeres shorten, eventually becoming so short that the cell is unable to divide properly anymore, leading to cell death. Now, the same researchers have found that telomeres hold a potent biological function that could be relevant to our understanding of cancer and aging.

Researchers at UNC School of Medicine (Chapel Hill, NC, USA) have made the stunning discovery that telomeres hold genetic information to produce two small proteins, one of which was found to be elevated in specific human cancer cells and cells from patients with telomere-related defects. In 2011, a group of researchers studying an inherited form of ALS found that an RNA molecule containing a six-base repeat could by a novel mechanism generate a series of toxic proteins consisting of two amino acids repeating one after the other. In the latest study, the researchers found a striking similarity of this RNA to the RNA generated from human telomeres, and believe that the same novel mechanism could be in play.

They conducted experiments to show how telomeric DNA can instruct the cell to produce signaling proteins termed as VR (valine-arginine) and GL (glycine-leucine). Signaling proteins are basically chemicals that trigger a chain reaction of other proteins inside cells that eventually lead to a biological function important for health or disease. The researchers then chemically synthesized VR and GL to examine their properties using powerful electron and confocal microscopes, accompanied by state-of-the-art biological methods. They found elevated amounts of VR protein in some human cancer cells and in cells from patients suffering from diseases as a result of defective telomeres.

“Based on our research, we think simple blood tests for these proteins could provide a valuable screen for certain cancers and other human diseases,” said Jack Griffith, the Kenan Distinguished Professor of Microbiology and Immunology and member of the UNC Lineberger Comprehensive Cancer Center. “These tests also could provide a measure of ‘telomere health,’ because we know telomeres shorten with age.”

“Many questions remain to be answered, but our biggest priority now is developing a simple blood test for these proteins. This could inform us of our biological age and also provide warnings of issues, such as cancer or inflammation,” added Griffith.

Related Links:
UNC School of Medicine 


New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Collection and Transport System
PurSafe Plus®
Alcohol Testing Device
Dräger Alcotest 7000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Pathology

view channel
Image: Sophie Paczesny, M.D., Ph.D and her team have made BIOPREVENT freely available for researchers and clinician to test and learn from (Photo courtesy of Cliff Rhodes)

AI Tool Uses Blood Biomarkers to Predict Transplant Complications Before Symptoms Appear

Stem cell and bone marrow transplants can be lifesaving, but serious complications may arise months after patients leave the hospital. One of the most dangerous is chronic graft-versus-host disease, in... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.